BidaskClub upgraded shares of Insulet Corporation (NASDAQ:PODD) from a buy rating to a strong-buy rating in a report issued on Friday.
A number of other research analysts have also issued reports on PODD. B. Riley restated a neutral rating and set a $44.00 price objective on shares of Insulet Corporation in a research report on Tuesday, May 9th. Jefferies Group LLC restated a buy rating and set a $58.00 price objective (up previously from $48.00) on shares of Insulet Corporation in a research report on Wednesday, August 9th. Northland Securities restated a buy rating on shares of Insulet Corporation in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $55.00 price objective on Insulet Corporation and gave the company a hold rating in a research report on Friday, August 4th. Finally, Cowen and Company restated an outperform rating and set a $63.00 price objective (up previously from $52.00) on shares of Insulet Corporation in a research report on Friday, August 4th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $50.46.
Insulet Corporation (NASDAQ PODD) traded down 1.18% during trading on Friday, reaching $57.18. 200,281 shares of the company’s stock were exchanged. Insulet Corporation has a 52 week low of $30.69 and a 52 week high of $58.48. The stock’s market capitalization is $3.32 billion. The stock has a 50-day moving average of $52.72 and a 200-day moving average of $46.15.
Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The business had revenue of $110 million during the quarter, compared to analyst estimates of $106.23 million. During the same quarter in the previous year, the firm posted ($0.08) EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, equities research analysts anticipate that Insulet Corporation will post ($0.50) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Insulet Corporation (PODD) Upgraded by BidaskClub to Strong-Buy” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/26/insulet-corporation-podd-upgraded-by-bidaskclub-to-strong-buy.html.
Hedge funds have recently bought and sold shares of the company. Lord Abbett & CO. LLC increased its stake in Insulet Corporation by 29.6% in the second quarter. Lord Abbett & CO. LLC now owns 838,302 shares of the medical instruments supplier’s stock worth $43,013,000 after buying an additional 191,217 shares in the last quarter. RNC Capital Management LLC purchased a new stake in Insulet Corporation during the second quarter worth approximately $225,000. The Manufacturers Life Insurance Company increased its stake in Insulet Corporation by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 44,746 shares of the medical instruments supplier’s stock worth $2,296,000 after buying an additional 198 shares in the last quarter. State Street Corp increased its stake in Insulet Corporation by 7.7% in the second quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock worth $61,014,000 after buying an additional 85,280 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Insulet Corporation during the second quarter worth approximately $27,428,000.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
